Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial

Thrombosis and Haemostasis

Volumn 98, Issue 2, 2007, Pages 392-396

  Qari, Mohamad Hasan ^a   Aljaouni, Soad Khalil ^a   Alardawi, Mohamad Salleh ^a   Fatani, Huda ^a   Alsayes, Fatin Mohamad ^a   Zografos, Panagiotis ^b   Alsaigh, Mohamad ^a   Alalfi, Adnan ^a   Alamin, Mohamad ^a   Gadi, Abdulilah ^a   Mousa, Shaker A ^c  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b Leo Pharmaceutical Products   (Greece)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Genetic disease; Heparin; Pain; Sickle cell anemia; Tinzaparin

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; MORPHINE; PLACEBO; TINZAPARIN;

ADULT; ARTICLE; BLEEDING; BLOOD VESSEL OCCLUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SICKLE CELL ANEMIA; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITALIZATION; HUMANS; MALE; PAIN; PAIN MEASUREMENT; VASCULAR DISEASES;

EID: 34547863870     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-12-0718     Document Type: Article

References (46)

1. Steinberg MH. Pathophysiologically based drug treatment of sickle cell disease. Trends Pharmacol Sci 2006; 27: 204-210.
2. Embury SH. Sickle cell disease. In: Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, eds. Hematology, Principles and Practice. 2nd ed. New York, Churchill Livingston 1995: 611-648.
3. Mousa SA, Johansen K. Pharmacodynamic effects of low molecular weight heparin tinzaparin in obese subjects following subcutaneous administration of 75 IU/kg on plasma tissue factor pathway inhibitor and nitric oxide. Int Angiol 2005; 24: 40-42.
4. Mousa SA. Elevation of plasma von Willebrand factor and tumor necrosis factor-a in obese subjects and their reduction by the low molecular weight heparin tinzaparin. Int Angiol 2005; 24: 278-281.
5. Mousa SA. Low-molecular-weight heparins in thrombosis and cancer: emerging links. Cardiovasc Drug Rev 2004; 22: 121-134.
6. Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, not anti-thrombotic activity. Clin Cancer Res 2005; 11: 7003-7011.
7. Wu O, Robertson L, Langhorne P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 2005; 94: 17-25.
8. Jaywant S, Pai A. A comparative study of pain measurement scales in acute bum patients. Ind J Occup Ther 2003; 35: 13.
9. Browne PV, Mosher DF, Steinberg MH, et al. Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol 1996; 51: 296-301.
10. Devine DV, Kinney TR, Thomas PF, et al. Fragment D-dimer levels: an objective marker of vaso-occlusive crisis and other complications of sickle cell disease. Blood 1986; 68: 317-319.
11. Hagger D, Wolff S, Owen J, et al. Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls. Blood Coagul Fibrinol 1995; 6: 93-99.
12. Key NS, Slungaard A, Dandelet L, et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998; 91: 4216-4223.
13. Kurantsin-Mills J, Ofosu FA, Safa TK, et al. Plasma factor VII and thrombin-anti-thrombin III levels indicate increased tissue factor activity in sickle cell patients. Br J Haematol 1992; 81: 539-544.
14. Kurantsin-Mills J, Ibe BO, Natta CL, et al. Elevated urinary levels of thromboxane and prostacyclin metabolites in sickle cell disease reflect activated platelets in the circulation. Br J Haematol 1994; 87: 580-585.
15. Nsiri B, Grith N, Bayoudh F, et al. Abnormalities of coagulation and fibrinolysis in homozygous sickle cell disease. Hematol Cell Ther 1996; 38: 279-284.
16. Peters M, Plaat BEC, ten Cate H, et al. Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost 1994; 71: 169-172.
17. Solovey A, Gui L, Key NS, et al. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest 1998; 101: 1899-1904.
18. Triadou P, Fonty E, Ambrosio AS, et al. Platelet functions in sickle cell disease during steady state. Nouv Rev Fr Hematol 1990; 32: 137-142.
19. Francis RB. Large-vessel occlusion in sickle cell disease: pathogenesis, clinical consequences, and therapeutic implications. Med Hypotheses 1991; 35: 88-95.
20. Kirkpatrick MB, Haynes J. Sickle cell disease and the pulmonary circulation. Semin Resp Crit Care Med 1994; 15: 473.
21. Murphy RC, Shapiro S. Pathology of sickle cell disease. Ann Intern Med 1945; 23: 376.
22. Pavlakis SG, Bello J, Prohovnik I, et al. Brain infarction in sickle cell anemia: magnetic resonance imaging correlates. Ann Neurol 1988; 23: 125-130.
23. Chiu D, Lubin B, Roelofsen B, et al. Sickled erythrocytes accelerate clotting in vitro: an effect of abnormal membrane lipid asymmetry. Blood 1981; 58: 398-401.
24. Hebbel RP, Boogaerts MA, Eaton JW, et al. Erythrocyte adherence to endothelium in sickle-cell anemia: a possible determinant of disease severity. N Engl J Med 1980; 302: 992-995.
25. Lubin B, Chiu D, Bastacky J, et al. Abnormalities in membrane phospholipids organization in sickled erythrocytes. J Clin Invest 1981; 67: 1643-1649.
26. Adams R, McKie V, Nichols F, et al. The use of transcranial ultrasonography to predict stroke on sickle cell disease. N Engl J Med 1992; 326: 605-610.
27. Chiang EY, Frenette PS. Sickle cell vaso-occlusion. Hematol Oncol Clin North Am 2005; 19: 771-784.
28. Semple MJ, Al-Hasani SF, Kioy P, et al. A double-blind trial of ticlopidine in sickle cell disease. Thromb Haemost 1984; 51: 303-306.
29. Zago MA, Costa FF, Ismael SJ, et al. Treatment of sickle cell diseases with aspirin. Acta Haematol 1984; 72: 61-64.
30. Chaplin H Jr, Monroe MC, Malecek AC, Morgan LK, Michael J, Murphy WA. Preliminary trial of mini-dose heparin prophylaxis for painful sickle cell crises. East Afr Med J 1989; 66: 574-584.
31. Evans EA, Mohandas N. Membrane-associated sickle hemoglobin: a major determinant of sickle erythrocyte rigidity. Blood 1987; 70: 1443-1449.
32. Setty BN, Chen D, Stuart MJ. Sickle cell vaso-occlusive crisis is associated with abnormalities in the ratio of vasoconstrictor to vasodilator prostanoids. Pediatr Res 1995; 38: 95-102.
33. Claster S, Vichinsky EP. Managing sickle cell disease. Br Med J 2003; 327: 1151-1155.
34. Styles LA, Lubin B, Vichinsky E, et al. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood 1997; 89: 2554-2559.
35. Kumar A, Eckman JR, Wick TM. Inhibition of plasma-mediated adherence of sickle erythrocytes to microvascular endothelium by conformationally constrained RGD-containing peptides. Am J Hematol 1996; 53: 92-98.
36. Kaul DK, Tsai HM, Liu XD, et al. Monoclonal anti-bodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood 2000; 95: 365-367.
37. Space SL, Lane PA, Pickett CK, et al. Nitric oxide attenuates normal and sickle red blood cell adherence to pulmonary endothelium. Am J Hematol 2000; 63: 200-204.
38. Morris CR, Morris SM Jr, Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003; 168: 63-69.
39. Head CA, Brugnara C, Martinez-Ruiz R, et al. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo [see comments]. J Clin Invest 1997; 100: 1193-1198.
40. Drexler H, Zeiher AM, Meinzer K, et al. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterotlaemic patients by L-arginine. Lancet 1991; 338: 1546-1550.
41. Creager MA, Gallagher SJ, Girerd XJ, et al. L-argi-nine improves endothelium-dependent vasodilatation in hypercholesterolemic humans. J Clin Invest 1992; 90: 1248-1253.
42. Kharitonov SA, Lubec G, Lubec B, et al. L-arginine increases exhaled nitric oxide in normal human subjects. Clin Sci (Lond) 1995; 88: 135-139.
43. Tsao PS, McEvoy LM, Drexler H, et al. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation 1994; 89: 2176-2182.
44. Mousa SA. Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects. J Clin Pharmacol 2003; 43: 727-734.
45. Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 2005; 11: 7003-7011.
46. Matsui NM, Varki A, Embury SH. Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood 2002; 100: 3790-3796.